St. Jude Medical won approval from Japanese regulators to market the Atlas II line of implantable cardioverter defibrillators. These high powered AICDs been cleared by the FDA back in July 2006.
Features from the product page:
High output (36 J delivered): Atlas II devices provide unsurpassed energy for defibrillation. DeFT Response™ technology: Many drugs have been shown to raise defibrillation thresholds to potentially unsafe levels.1-3 Unique DeFT Response technology tools provide more clinically proven, noninvasive options for managing high DFTs. SenseAbility® technology: SenseAbility feature with Decay Delay and Threshold Start provides the flexibility to fine-tune sensing to individual patient needs and help eliminate the over-sensing of T waves, far-field R waves, fractionated QRS complexes and other extraneous signals. DC Fibber™ induction: Exclusive DC Fibber VF induction has a documented 95.5% success rate for inducing fibrillation on the first induction as compared to a 72.7% success rate for Shock-on-T. AF Suppression™ algorithm (Atlas II+ DR only): Proprietary AF Suppression algorithm is clinically proven to suppress episodes of paroxysmal and persistent AF. Studies show a 25% decrease in symptomatic AF burden. QuickOpt® timing cycle optimization (DR models only): IEGM-based AV optimization allows optimized timing without the need for echo-guided optimization. QuickOpt timing provides quick and effective optimization for more patients at the push of a button.
Press release: St. Jude Medical Announces Japanese Approval of Atlas II ICD
Product page: Atlas® II ICD Family
Flashback: New Defibrillator Features AF Suppression Technology
